The effects of growth hormone (GH) treatment on 24-h energy expenditure (EE) were studied in a open trial over a period of 4 weeks. Five subjects, four men and one woman, with a history of complete GH deficiency were included. All the subjects were examined on 2 consecutive days on baseline and, thereafter, at six occasions during a period of 1 month (days 1, 2, 5, 8, 15, and 30). The dose of GH was 0.25 U/kg⅐week, administered sc once a day in the evening.
S
EVERAL recent studies have indicated that growth hormone (GH) plays an important role in adults. GH, or the lack of it, has profound effects on several metabolic variables in normal, obese, and GH-deficient subjects (1, 2, 3, 4) . After 6 weeks of recombinant human GH treatment in GH-deficient patients, there is a marked change in body composition, with an increase in lean body mass and a decrease in adipose tissue (AT) (1, 4) .
We recently have shown that GH-deficient adults (GHD) have a basal metabolic rate (BMR) in the lower part of the normal range but not significantly different from healthy controls (5) . This was evident when the absolute BMR value was used or when BMR was expressed per kg of fat-free mass (FFM) or adjusted for age, body fat (BF), and FFM.
It is known that BMR and BMR/FFM increases during treatment with GH (5, 6) . It has been suggested that the increase in BMR is mediated via changes in body composition and increases in protein synthesis and/or the deiodination of T4 to T 3 (see Ref. 23) . However, it is still unclear whether GH also has a direct effect on energy expenditure (EE). Furthermore, the within-and in-between day variability in the EE response to GH are largely unknown; and 24-h EE (24hEE), sleeping metabolic rate (SMR), BMR, and daytime EE (DayEE) have never been examined in a chamber for indirect calorimetry.
The aims of the present study were to evaluate EE in GHD further and to examine differences in EE within and inbetween days during the first 4 weeks of GH treatment in GH-deficient subjects. We also aimed to study time-dependent changes in EE in relation to changes in body composition and metabolic markers such as insulin-like growth factor 1 (IGF-I), thyroid-related hormones, and the aminoterminal procollagen III peptide (PIIIp).
Materials and Methods

Study protocol
The study was designed as an open study. Before the start of treatment, all the subjects were examined on 2 consecutive days. During GH treatment, all the subjects were examined on days 1, 2, 5, 8, and 15 and after 1 month in the chamber. (On day 5, chamber results were not available for subject no. 4 because of acute gastro-enteritis.) The subjects were not allowed to leave the chamber between the 2 baseline examination days or between the 1st and 2nd examination day. The mean of the two baseline values was used as a pretreatment value.
Study subjects
Four men and one woman, 23-67 yr old, were examined. All the subjects had been GH-deficient for more than 1 yr and were included in the study according to the following criteria: 1) a maximal GH concentration peak of less than 5 mU/L after an iv insulin tolerance test (0.1 IU insulin/kg BW) (all the patients displayed symptoms of hypoglycemia and had a blood glucose level less than 2.2 mmol/L); 2) the patients had been on stable replacement therapy with corticosteroids, L-T 4 , and gonadal steroids for at least 1 yr before the study.
The individual characteristics of the five patients are shown in Table  1 . Three male patients had been treated with irradiation after pituitary surgery. One male patient had hypopituitarism caused by an apoplexy in a pituitary adenoma. One woman had had idiopathic hypopituitarism since childhood. Two of the subjects included in the study had received treatment with GH during childhood. None of the patients was a current smoker. One patient was being treated for hypertension with a calcium blocker (Isradipin).
The patients received both written and verbal information about the nature of the study, and their written informed consent was obtained. The study was approved by the Ethics Committee at the Medical Faculty at Gö teborg University.
Treatment
The dosage of GH was 0.25 U/kg BW⅐week (12 g/kg BW⅐day), administered as a daily evening sc injection by the patient (PharmaciaUpjohn, Uppsala, Sweden). The first injection was given on day 1. Between the injections, the vials were stored for a maximum of 7 days at 5-12 C, protected from the light. No reduction in the dose because of side-effects was necessary during the study period.
Basal medication
The patients were on stable medication with glucocorticoids (cortisone acetate 12.5 mg twice a day), L-T 4 (0.10 -0.20 mg/day), and sex hormones. Two subjects were being treated with ADH (Desmopressin) ( Table 1 ). The dose of cortisone acetate was not changed during the GH study, except in the case of intercurrent illnesses.
Calorimetric methods
EE was determined by indirect calorimetry in a 30-m 3 metabolic chamber, as previously described (7). The mathematical procedures followed those described by Brown et al. (8) . The protein oxidation was calculated from urinary nitrogen excretion. For repeated changes, the time resolution of the chamber was approximately 15 min, as shown by intermittent infusions of a nitrogen/CO 2 mixture (80:20). The oxygen and CO 2 analyzers were calibrated before each experiment by blending fresh air with N 2 or CO 2 using a gas blender (Environics Inc, Willington, CT). The overall response of the chamber was regularly validated by butane combustion experiments. The system was shown to be accurate within Ϯ1.2% in 95% of the tests (7). The precision error calculated from double determinations in the same subjects on consecutive days before GH treatment was 4.1% for 24hEE, 4.6% for BMR, and 3.0% for SMR. The study participants entered the chamber at 1000 h. During the day, subjects were encouraged to be as active as they wished, but no vigorous exercise was allowed. The subjects were instructed to go to bed at 2200 h and were awakened at 0630 h. The subjects fasted from 2200 h until after the BMR measurement in the morning. Participants were removed from the chamber at 1100 h. During the chamber experiment, all the subjects filled in an activity diary. All the subjects received dietary instructions before starting the study and were instructed not to change their dietary intake over the study period. During the chamber examinations, an isocaloric diet was served.
EE measurements. EE data were obtained for the following periods:
Total 24hEE. EE during the total 24-h stay in the chamber. SMR. EE between 0100 and 0600 h, excluding all periods of awakening related to toileting, for example.
BMR. EE measured between 0700 and 0740 h, with the subject resting on the bed in the chamber after an overnight fast.
DayEE. EE between 1300 and 1800 h.
Single injection of GH. The effects of one sc injection of GH were studied during the first day of treatment. EE measured during the hour preceding the first GH injection was compared with the EE measured during each consecutive hour for 5 h.
Measures of dispersion. The root of the mean squared successive differences (RMSSD) and the sd were calculated for the above described periods. The RMSSD has previously been used primarily in studies of blood pressure and has been shown to be a sensitive and almost pure measure of short-term variability (9) . It also has been shown to be resistant to slow rhythms and linear trends, and it was therefore used in this study as a complement to sd to characterize the shape of the EE curve.
Predicted BMR. An estimation of BMR from weight, height, age, and sex was made according to standard equations described in Ref. 10 .
Body composition
All measurements of body composition were made before each chamber experiment on days Ϫ3, Ϫ2, 2, 8, 15, and after 30 days.
Body weight was measured with the patients dressed in underwear and was determined to the nearest 0.1 kg on a calibrated scale. Body height was measured without shoes, in the standing position, to the nearest 0.1 m. Body mass index (BMI) was calculated as BW divided by height 2 .
Dual-energy x-ray absorptiometry. All the subjects were examined with PDX-L equipment produced by Lunar Corp., Madison, WI. Determinations of total body, BF, lean weight, and bone mineral content (BMC) were determined. FFM was calculated as lean weight plus BMC. The calculated error of a double determination in the same subject was 0.95% for BMC, 1.6% for lean weight, and 1.5% for BF.
Computed tomography. One longitudinal and four transsectional scans were obtained. All the subjects were examined at baseline and after 4 weeks on GH. The transsectional scans were obtained at L3, the iliac crest, thigh, and calf. Visceral and sc AT and muscle areas were determined by defining AT as tissues in the attenuation interval Ϫ190 to Ϫ30 HU, as previously described (11) . Muscle and sc areas were determined as the mean of all scans. Visceral adipose area was determined as the mean of the L3 and the iliac crest scan.
Biochemical methods
GH concentrations in serum were determined using a polyclonal immunoradiometric assay method (Pharmacia), and IGF-I was determined by an RIA (Nichols Institute, Wijehen, the Netherlands). IGFbinding protein-3 (IGFBP3) was determined using an RIA (Nichols Institute). Serum-free T 4 (free T 4 ) and free T 3 were analyzed using ligand analog RIAs (Amerlex M, Amersham International plc, Amersham, Bucks, UK), serum total T 4 using a single-antibody RIA (Farmos Diagnostica, Turku, Finland), total T 3 using a polyethylene-glycol assisted double-antibody RIA (Diagnostic Products Corp, Los Angeles, CA), reverse T 3 was determined by an RIA (Ares Serono, Milano, Italy), and PIIIp using an immunoradiometric assay (Hoechst-Behringwerke, Marburg, Germany). Blood samples were drawn in the morning of days Ϫ3, Ϫ2, 2, 5, 8, 15, and day 30 after an overnight fast. All the samples from each patient were run in the same assay and in complete blocks. 
Statistical methods
Statistical calculations were carried out on a Vax 4100 computer using the Minitab statistical program, version 9. Comparisons between baseline (the mean value for the two baseline examinations) and consecutive examinations were made using a paired t test. Descriptive statistics and Spearman's rank correlation coefficients were used at baseline.
In addition to the baseline observations, the study included repeated simultaneous measurements of EE, body composition, and biochemical variables on six different occasions with time intervals according to Fig.  1 . A two-stage method was used for the time-dependent statistical analysis. First, the repeated measurement from each patient was reduced to one summary variable reflecting the time-dependent association between two variables. Second, the summary variable (Spearman's rank correlation coefficient) was analyzed in a univariate fashion (12) by paired t tests. A P-value less than 0.05 was considered statistically significant.
Results
Baseline
At baseline, no significant difference was found between BMR measured in the chamber and the calculated reference BMR (BMR-predicted), adjusted for sex, age, body weight, and height [1610 Ϯ 410 vs. 1700 Ϯ 410 kcal/24 h; NS (not significant)]. 24hEE, SMR, and BMR were all correlated to BW and FFM (not shown). 24hEE and SMR also tended to be correlated to BF (not shown). All the subjects had a BMR/ SMR ratio above 1.0.
Effects of treatment
EE. The treatment with GH increased 24hEE, SMR, and BMR in all subjects. No alteration in DayEE was found over the study period ( Table 2 ). The maximum increase in 24hEE, SMR, and BMR was seen within the first 2 weeks of treatment (Fig. 1) . Thereafter, no further significant change could be detected. SMR and BMR increased more markedly than 24hEE (Fig. 2) . During the first 2 weeks of treatment, 24hEE increased by a mean of 6 Ϯ 3% (range 1-8%) from 40.9 Ϯ 4.8 to 42.9 Ϯ 4.8 kcal/24 h⅐kg (P Ͻ 0.05), SMR by 14 Ϯ 3% (range 10 -18%) from 28.4 Ϯ 1.9 to 32.9 Ϯ 2.2 kcal/24h⅐kg (P Ͻ 0.001), and BMR by 11 Ϯ 7% (range 0 -18%) from 29.6 Ϯ 2.4 to 33.3 Ϯ 2.6 kcal/24h⅐kg (P Ͻ 0.05). (Table 2 ). The lipid oxidation had increased by 61 Ϯ 36 mg/min (136%) at day 15 (P ϭ 0.02) ( Table 2) .
After 2 weeks of treatment, the variability in EE increased in four of five subjects (SMR-RMSSD: 34 Ϯ 9 vs. 46 Ϯ 15 cal/min; P ϭ 0.069).
No significant effect from the first single injection of GH on EE or RQ was found (not shown).
Body composition. BW increased by a mean of 1.5 Ϯ 0.6 kg after 2 weeks and was then virtually unchanged at 4 weeks (77. Serum IGF-I, IGFBP-3, and PIIIp. IGF-I increased from a mean of 79 Ϯ 61 g/L at pretreatment to a mean of 220 Ϯ 130 g/L within the first 2 days of treatment. A similar pronounced increase also was found in IGFBP-3, which increased from 1.6 Ϯ 1.0 mg/L at baseline to 2.4 Ϯ 1.3 mg/L during the first 2 days. A marked, but more gradual, increase was found in PIIIp during the first 2 weeks of treatment ( Fig. 1 and Table 3 ).
Thyroid-related hormones. A significant increase of 25-30% in total and free T 3 was detectable after 8 days of treatment. Total T 4 did not change over the study period, but a decrease in free T 4 was detectable after 4 weeks of treatment (Table 3) . The ratio of free T 3 /free T 4 increased markedly during the first week of treatment, and the maximum increase was found within the first 2 weeks of treatment (Fig. 1) . After 2 weeks, there was a tendency towards a transient decrease in reverse T 3 (Table 3) . Heart rate and blood pressure were unchanged over the study period (not shown).
Correlation analysis. The correlation coefficient between delta values for changes in EE and delta values for changes in FFM, BF, FT 3 /FT 4 , PIIIp, IGF-I, and IGFBP-3 were calculated separately for each examined subject. The individual correlation coefficients were then averaged, and the possibility of a covariation was evaluated by paired t tests. Delta SMR covaried significantly with delta FT 3 /FT 4 (r ϭ 0.72 Ϯ 0.17; P Ͻ 0.001), delta IGF-I (r ϭ 0.70 Ϯ 0.27; P Ͻ 0.01), delta PIIIp (r ϭ 0.65 Ϯ 0.17; P ϭ 0.011), and delta IGFBP-3 (r ϭ 0.65 Ϯ 0.41; P Ͻ 0.01) but not with delta FFM (r ϭ 0.40 Ϯ 0.34; NS) and delta BF (r ϭ Ϫ0.08 Ϯ 0.71; NS). Similar covariations also were found between delta SMR adjusted for FFM and delta FT 3 /FT 4 , delta IGF-I, delta PIIIp, and delta IGFBP-3 (not shown).
Discussion
The present study was designed to examine the early effects of GH treatment on 24hEE in subjects with GHD and to analyze the time-response relationships between changes in EE and body composition and different metabolic factors. The GH treatment was found to increase 24hEE, SMR, and BMR (but not DayEE). The maximal response was observed after 14 days, and 50% of the maximal response was obtained after just 3 days. The main increase in EE occurred gradually over the first 2 weeks. A covariation was found between the increase in EE and changes in several metabolic factors, but no relationship was found between changes in EE and changes in body composition over the first 4 weeks of treatment.
In studies of subjects with GH deficiency, EE has been reported to be normal or low-normal (13, 5, 14) , as well as increased (after adjustment for FFM) (15) . In the present study, BMR was not significantly lower than the predicted value. In our previous report, subjects with GHD had a mean BMR that was in the low-normal range if standard prediction equations were used. Furthermore, BMR and BMR/FFM were unchanged, compared with controls matched for sex, age, and BMI (5). Similar observations were made by Hoffman et al. (13) . Using doubly-labeled water (DLW), Chong et al. (14) found similar total EE in GH-deficient subjects as compared with normal subjects. In contrast, Salomon et al. (see discussion in Ref. 5 ) observed an increase in BMR/FFM in GHD subjects, possibly caused by a poorly selected control group.
The metabolic stimulatory potential of GH has been established in several studies (1, 5, 15) . GH treatment in normal, obese, and GHD has been found to increase BMR and to increase lipid oxidation (5) , resulting in a decrease in BF and an increase in muscle and visceral organ weight (1) . Using the DLW technique, Chong et al. (14) found that 2 weeks of GH treatment increased total EE by approximately 13%. We found a slightly lower increase in 24hEE (8%). The difference may be related to a larger degree of restriction in spontaneous physical activity in the chamber, but also to much larger (7) . The first injection of GH failed to produce any significant effect on EE. In contrast, short-term studies have reported an acute effect by GH (17) on EE, whereas others have failed to show any such effect (18, 19) . Our study demonstrated a detectable increase in EE after 2 days of treatment. The response time may, however, be dose-dependent, considering that larger doses have been shown to increase EE more rapidly (20) .
The increase in EE seemed to occur progressively over a 2-week period, and no further increase was then observed.
We used a protocol involving repeated examination during the first 4 weeks, and the relationship between changes in EE and changes in body composition and certain metabolic variables was examined using a two-step procedure (12) . The increase in EE covaried with the free T 3 /free T 4 ratio, IGF-I, IGFBP-3, and PIIIp, but no covariation was found with changes in body composition. These results support previous findings that the effect of GH on energy metabolism is not solely explained by changes in body composition (4) .
IGF-I has been shown to increase EE in the same way as GH (21) . IGF-I also has an additive effect on EE in addition to the effect of GH (22) . It is, however, unclear whether IGF-I has a direct effect on EE. It has been suggested that the effect of IGF-I on EE is mediated by secondary metabolic changes (21) .
Like others, we observed an increase in free and total T 3 concentrations and a tendency towards a decrease in free T 4 , suggesting the increased deiodination of T 4 to T 3 during GH treatment (6) . The maximum response was found after 2 weeks, and 50% of the maximum response was detectable after 5 days. GH treatment, therefore, seems to have an acute effect on thyroid function. Studies using larger doses have shown effects even after 4 days (23), indicating a dose-response effect. However, the increase in T 3 concentrations probably does not explain fully the calorigenic effect of GH. Experimental studies in normals and obese subjects have shown that the addition of GH to T 3 treatment further increased EE (24, 25) . GH thus seems to mediate its effects on EE through several different mechanisms.
A more marked increase was found in SMR and BMR than in 24hEE, and no change was found in DayEE. These findings suggest that the calorigenic effect of GH varies during the day, with a more pronounced increase during the night and morning hours, possibly because of higher serum GH concentrations after the evening injection (26) . This could suggest a direct effect by GH on EE.
The predominant consumer of energy in the cell is the Na ϩ , K ϩ ATPas, and it has been suggested that GH alters EE through changes in the activity of the Na ϩ , K ϩ pump (either at the expression or posttranslational level) (27) . We therefore hypothesize that the observed predominately nightly increase in EE might be mediated through GH-induced alterations in Na ϩ , K ϩ ATPas activity. To summarize, we have examined 24hEE changes during the first 4 weeks of treatment with GH. We found that GH increases 24hEE, BMR, and SMR (but not DayEE). The main increase in EE seemed to occur gradually over the first 2 weeks of treatment and covaried with changes in several metabolic factors, but no relationship was found between changes in EE and changes in body composition.
